

## **SUPPLEMENTAL MATERIAL**

**Exploring ubiquinone biosynthesis inhibition as a strategy for improving atovaquone efficacy in malaria**

**Verdaguer I.B.<sup>a§</sup>; Crispim M.<sup>a§</sup>; Zafra C.A.<sup>a</sup>; Sussmann R.A.C.<sup>b</sup>; Buriticá L.<sup>a</sup>; Melo H.R.<sup>c</sup>; Azevedo M.F.<sup>c</sup>; Almeida F.G.<sup>a</sup>; Kimura E.A.<sup>a</sup>; Katzin A.M.<sup>a#</sup>.**

**<sup>§</sup>These authors contributed equally to this work. Author order was determined by drawing straws.**

**<sup>a</sup>Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo. Av. Lineu Prestes 1374, Cidade Universitária (05508-000), Butantã, São Paulo - SP, Brazil.**

**<sup>b</sup>Center for Environmental Sciences; Institute of Humanities, Arts and Sciences; Federal University of Southern Bahia, Brazil.**


**<sup>c</sup>Departament de Bioscience, Federal University of São Paulo, Santos - SP, Brazil.**

**<sup>#</sup>Corresponding author: Alejandro M. Katzin.**


**Tel.: +55-11-3091-7330. Fax: +55-11-3091-7417. e-mail: amkatzin@icb.usp.br.**

**Running title: Drug-targeting ubiquinone for malaria**







**Fig S1. Malaria parasite culture under normal or microaerophilic conditions.** *P. falciparum* cultured under normal (a) or microaerophilic conditions (b). This was adopted to observe the changes in blood color. *P. falciparum* 3D7 isolate was cultured *in vitro* as described in the materials and methods and a gaseous mixture of 5% CO<sub>2</sub>, 5% O<sub>2</sub>, and 90% N<sub>2</sub> was employed as a reference. However, oxygen-free mixtures (5% CO<sub>2</sub> and 95% N<sub>2</sub>) were used in certain experiments until the culture attained a chocolate-brown color.




**Fig S2. [<sup>3</sup>H] GGPP incorporation into ubiquinones.** **a:** RP-HPLC metabolic profiles of erythrocytes uninfected or infected with *P. falciparum* schizonts. Uninfected or infected erythrocytes were incubated with [<sup>3</sup>H] GGPP. **b** and **c:** UQ-8 (b) or UQ-9 (c) from [<sup>3</sup>H] GGPP-radiolabeled parasites were purified by RP-HPLC. Both UQ homologs were chemically reduced and analyzed by the same chromatography method. In all experiments, samples were co-injected with UQ standards. The fractions were collected at 1 min. CPM: counts per minute. This experiment was performed twice with similar results.



**Fig S3. Incorporation of radiolabeled precursors into ubiquinones.** RP-HPLC metabolic profiles of erythrocytes infected with *P. falciparum* schizonts incubated with different radiolabeled metabolites, as indicated. In all experiments, the samples were co-injected with UQ standards. The fractions were collected at 0.75 min. CPM: counts per minute. Glc: [<sup>14</sup>C-U] Glc, SAM: [methyl-<sup>3</sup>H] SAM, FPP: [<sup>3</sup>H] FPP, 4-HB: [ring-<sup>14</sup>C]-4-HB. These experiments were performed twice for each radiolabeled precursor and all experiments yielded similar results.




**Fig S4. Atovaquone rescue assays.** IC<sub>50</sub> values and sigmoidal dose-response curves of AV at 48 h in the presence or absence of 5  $\mu$ M dUQ, 5  $\mu$ M or 10  $\mu$ M UQ-10 (mean of three identical experiments). This experiment was performed thrice by DNA staining, as described in methodological procedures.




**Fig S5. Atovaquone potentiation by 4-nitrobenzoate is not general or nonspecific.** The obtained dose-response curves along with the R<sup>2</sup> values (mean of three experiments) corresponding to treatment with AV for 48 h (a) or 72 h (b). The same experiment was performed by treatment with chloroquine (CQ) for 72 h (c). Both assays were performed in the presence or absence of 4-NB at the indicated concentrations, and the effects were observed using flow cytometry (FACS). iRBC: infected red blood cells. Parasites harvested by centrifugation were resuspended in a solution of 10  $\mu$ g/mL ethidium bromide in PBS and incubated at 37 °C for 20 min. This was followed by washing and resuspension in PBS and analysis using a Guava Easycyte Flow Cytometer (Merck). To confirm that the parasites cultivated in the presence of 4-NB were more susceptible to AV, these were cultured for 48 h

in the presence, or absence of 0.125 to 1 mM 4NB and a series of AV dilutions were prepared. Parasitemia was determined using flow cytometry (FACS) and the results were analyzed as described in materials and methods. The specificity of AV potentiation by 4-NB was investigated by determining chloroquine-sensitivity in the presence and absence of 4-NB. The IC<sub>50</sub> values of chloroquine were similar, indicating that the effects of 4-NB are not general or nonspecific.





**Fig S6. Effects of 4-nitrobenzoate on the growth of malaria parasite.** Sigmoidal dose-response curves of the effect of 4-NB at 48 h (a) or 72 h (b). This experiment was performed thrice by DNA staining, as described in materials and methods.



**Fig S7. 4-Nitrobenzoate does not affect initial rate of respiration.** Comparison of total cellular oxygen consumption (R') between untreated and 4NB-treated *P. falciparum* parasites. This experiment was performed thrice as described in methodological procedures. Unpaired t-test was used for statistical analysis to compare the values corresponding to the R'. ns: difference not statistically significant.